How Enabling Drug Delivery Innovation Gets Better Medicines to Patients
Last year Moderna’s former head of infectious disease described vaccine lipid nanoparticle (LNP) delivery technology “unsung hero of the whole thing.” The whole thing being the mRNA COVID-19 vaccine administered to hundreds of millions around the globe, through both Pfizer and Moderna. Proper delivery that protected the fragile messenger RNA molecular was critical in making […]
How Alloy is Democratizing T Cell Receptor (TCR) Therapy Discovery
At Alloy Therapeutics our goal is to empower drug discovery teams with technologies and services enabling them to make the best medicines for patients. Our company started this work in antibodies with a long-term plan to expand innovation to “adjacent modalities” that require similar expertise and could leverage much of our core antibody discovery, protein […]
How Our Mytide Investment Supports the Peptides Ecosystem
Peptides are a promising therapeutic modality in that they are small and specific in their targeting, while being relatively inexpensive to manufacture. Insulin is perhaps the best-known therapeutic peptide, but since 2000 33 non-insulin peptide therapeutics have been approved, spanning treatments for HIV, chronic pain, metabolic disease, cancer, cardiovascular disease, and more. Improvements in production, […]
Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning
Biotech ecosystem company Alloy Therapeutics leads the round, joined by Uncommon Denominator and Mytide founders BOSTON, March 8th, 2021–Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, has raised $7 million in Series A financing. The round was led by Alloy Therapeutics, a biotechnology ecosystem company, and was joined by Uncommon […]
Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering
The Basel, Switzerland-based deepCDR team and technology will strengthen Alloy’s antibody discovery platform and services for its ecosystem of 100+ global partners Boston, MA, USA and Basel, Switzerland, December 9th, 2021 – Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and […]
Alloy Therapeutics and Echo Investment Capital Create Wheeler Bio to Accelerate the Development of New Antibody Therapeutics
Wheeler Bio is a biomanufacturing company co-founded by Alloy Therapeutics and Echo Investment Capital to accelerate antibody therapeutics from discovery to IND. Operating out of Oklahoma City and Boston, Wheeler integrates cGMP manufacturing with Alloy’s discovery ecosystem to provide emerging biopharma companies a predictable, high-speed path to clinical trials. BOSTON, MA & OKLAHOMA CITY, OK, […]
Vernal Biosciences Launches to Democratize Access to High Quality mRNA Manufacturing
Seed Financing Will Scale Company’s Technology and Business Operations to Serve Clients of All Stages Vernal Biosciences launched with seed financing led by Alloy Therapeutics to democratize access to high-purity mRNA manufacturing for research and clinical-stage programs. Led by mRNA veteran Christian Cobaugh, Vernal provides a scalable manufacturing platform within the Alloy biotechnology ecosystem to […]